Media Articles Related to Maxalt-Mlt (Rizatriptan)
Migraine Linked to Higher Stroke Risk After Surgery
Source: Medscape General Surgery Headlines [2017.01.13]
Surgical patients with migraine are at increased risk for perioperative ischemic stroke and hospital readmission within 30 days of discharge, a new study finds.
Medscape Medical News
Migraine associated with higher risk of stroke after surgery
Source: Headache / Migraine News From Medical News Today [2017.01.12]
Surgical patients with a history of migraines have a greater risk of stroke and readmission to hospital, finds a study published by The BMJ.
Migraine Tied to Perioperative Stroke Risk (CME/CE)
Source: MedPage Today Neurology [2017.01.10]
(MedPage Today) -- 30-day ischemic stroke risk higher for those with migraine with aura
Retinal Migraine: Causes, Symptoms, and Treatment
Source: Eye Health / Blindness News From Medical News Today [2016.12.31]
Retinal migraine is a condition that affects some people who get migraine. Visual disturbances develop in one eye, followed by migraine symptoms.
UC researchers affirm diet can impact migraines
Source: Headache / Migraine News From Medical News Today [2016.11.02]
Eliminating that morning 'Cup of Joe,' consuming processed foods high in nitrites or monosodium glutamate (MSG) and enjoying too much alcohol are potential headache triggers for individuals...
Published Studies Related to Maxalt-Mlt (Rizatriptan)
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, cross-over, multicenter, Italian,
comparative study versus rizatriptan. 
The objectives of this study are to assess the efficacy and safety of
frovatriptan, and rizatriptan in the subgroup of women with menstrually related
migraine of a multicenter, randomized, double blind, cross-over study. Each
patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized
sequence: after treating 3 episodes of migraine in not more than 3 months with
the first treatment, the patient had to switch to the other treatment...
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
Clinical Trials Related to Maxalt-Mlt (Rizatriptan)
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) [Completed]
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed
drug in pediatric subjects with migraines.
After completion of a portion of the study (Panels A and B), a regulatory agency issued an
amended request that the 12-17 year old age group studied should include a similar number of
male and female subjects. Therefore, the study was amended to add an additional panel of
subjects (Panel C) to ensure gender balance specifically in this age group.
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Withdrawn]
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) [Completed]
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) [Completed]
A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine
attacks and duration of relief provided. This study will also provide additional efficacy
data on rizatriptan 5 mg and 10 mg for the treatment of migraine.
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) [Completed]
Reports of Suspected Maxalt-Mlt (Rizatriptan) Side Effects
Drug Ineffective (3),
Intestinal Ischaemia (2),
Abdominal Pain (1),
Cardiac Tamponade (1),
Sudden Death (1),
Abortion Spontaneous (1),
Drug Label Confusion (1), more >>